Related references
Note: Only part of the references are listed.Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Esraa M. Eloseily et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
F. Locatelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation
Lauren K. Meyer et al.
BLOOD (2020)
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
Paul La Rosee et al.
BLOOD (2019)
A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America
Amy M. Coffey et al.
PEDIATRIC BLOOD & CANCER (2019)
Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO)
Michael B. Jordan et al.
PEDIATRIC BLOOD & CANCER (2019)
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial
Asra Ahmed et al.
LANCET HAEMATOLOGY (2019)
Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib
Scott R. Goldsmith et al.
BLOOD ADVANCES (2019)
Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience
Inuk Zandvakili et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study
Elisabet Bergsten et al.
BLOOD (2017)
Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis
Larisa Broglie et al.
BLOOD ADVANCES (2017)
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
Rupali Das et al.
BLOOD (2016)
Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies
Pilar Brito-Zeron et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Therapeutic Role of Anakinra, an Interleukin-1 Receptor Antagonist, in the Management of Secondary Hemophagocytic Lymphohistiocytosis/Sepsis/Multiple Organ Dysfunction/Macrophage Activating Syndrome in Critically III Children
Surender Rajasekaran et al.
PEDIATRIC CRITICAL CARE MEDICINE (2014)
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T. Teachey et al.
BLOOD (2013)
Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens
DeepakBabu Chellapandian et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Salvage Therapy of Refractory Hemophagocytic Lymphohistiocytosis With Alemtuzumab
Rebecca A. Marsh et al.
PEDIATRIC BLOOD & CANCER (2013)
Etanercept for therapy-resistant macrophage activation syndrome
Balahan Makay et al.
PEDIATRIC BLOOD & CANCER (2008)
Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis
T Henzan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
An animal model of hemophagocytic lymphohistiocytosis (HLH):: CD8+ T cells and interferon gamma are essential for the disorder
MB Jordan et al.
BLOOD (2004)
Share Paper
